Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis

202429 citationsJournal Article

Authors

Zobair M. Younossi · Inova Health System

Maria Stepanova · Inova Health System

Andrei Racila · Inova Health System

Linda Henry · Inova Health System

Dominic Labriola · Madrigal Pharmaceuticals (United States)

Rebecca Taub · Madrigal Pharmaceuticals (United States)

Fatema Nader ·

Abstract

Patients with MASH/NASH with fibrosis improvement or the resolution of MASH with resmetirom experienced clinically meaningful and statistically significant HRQL improvements.

Topics & Keywords

Growth Hormone and Insulin-like Growth Factors Liver Disease Diagnosis and Treatment Diet and metabolism studies

Publication Details

Published in: Hepatology

Volume 81, Issue 4, pp. 1318-1327

DOI: 10.1097/hep.0000000000001084

Field-Weighted Citation Impact: 10.28

Command Palette

Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis

Authors

Abstract

Topics & Keywords

Publication Details